entertainment -WSS

entertainment

author：leisure time 2025-09-29 17:26:59 - browse：6

Stephen Quake: "Our North Star for the next decade is understanding the mysteries of the cell." Chan Zuckerberg Initiative

SAN DIEGO — Decades ago, as a young physics Ph.D. student, Stephen Quake stumbled into the messy, dazzlingly complicated world of biology — and he’s stayed there ever since.

Quake, a professor of bioengineering and applied physics at Stanford, is a prolific academic whose discoveries have fueled the field of blood-based prenatal testing and the use of microfluidic chips, which allow scientists to quickly analyze DNA, RNA, proteins, and cells. He’s also head of science for the Chan Zuckerberg Initiative, or CZI, a company Mark Zuckerberg and Priscilla Chan founded in 2015 with the expressed intent to help “cure, prevent or manage all diseases by the end of this century.” The organization funds academic research and operates three biohubs in San Francisco, Chicago, and New York, each centered on goals such as building cells that can survey the body for signs of disease or deciphering the signals that drive inflammatory disease.

STAT sat down with Quake in front of an audience during the annual meeting of the Biotechnology Innovation Organization for a fireside chat about his pivot into the life sciences — and his second unexpected journey into the world of philanthropy.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： FDA approves world's first CRISPR

WSS

Scrutiny of post

ASCO eve: Let’s set the table for this year's meeting

As a primary care physician, here's how I hope to partner with AI

Listen: More tumult at BIO & coercive care for sickle cell patients

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

Supreme Court wrestles with OxyContin maker's bankruptcy deal

Wikipedia

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

hotspot

Medicare details structure of new drug price negotiation program

Cue Health, Covid

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

After affirmative action ruling, medical educators look to 'holistic review'

Bird flu surveillance in wastewater gets boost from consortium

Cancer drug shortages should be causing more outrage

Questions and answers about ramping up H5N1 bird flu vaccine

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Pfizer plans to depart BIO

knowledge

Leukemia patients are helped by Syndax's new type of therapy

Liver decline slowed by off

FDA approves world's first CRISPR

Listen: More tumult at BIO & coercive care for sickle cell patients

Fentanyl is making it harder to start addiction treatment

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

explore

hotspot

focus

focus